Fluxus

Quick links to important sections

Fluxus

Treatment option: Carcinoma

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fluxus

Property Description
Active ingredient Flutamide
Form Oral Capsule
Pharmacological class Nonsteroidal Antiandrogen (NSAA)
General purpose To block male hormone effects
Origin Synthetic, First-Generation Compound

What is the Medicine Fluxus and its Active Ingredient?

The medicine Fluxus is a prescription-only, synthetic pharmaceutical preparation whose single active ingredient is Flutamide (INN). Flutamide's chemical definition is 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide. This monotherapy agent is manufactured as an oral capsule for consumption by mouth, making it an orally active agent. Flutamide is identified as an antineoplastic agent, a classification that characterizes the drug's specialized role in addressing conditions related to cell growth throughout its therapeutic use.


What Type of Drug is Flutamide?

Flutamide is classified as a specialized Nonsteroidal Antiandrogen (NSAA) and belongs to the larger therapeutic categories of Hormonal Agent and Antineoplastic Agent. This classification signifies that the drug's primary action involves interfering with the body’s natural hormones to regulate the growth of specific cells. It is recognized as a first-generation NSAA, distinguishing it from newer antiandrogens and different classes of hormonal therapies. As an androgen receptor antagonist, Flutamide functions by actively blocking the signal from male hormones, positioning it as a foundational therapy in its class.


How Does Fluxus Relate to Male Hormones?

The general purpose of Fluxus is to control the effect of natural male hormones, or androgens, specifically testosterone and its potent metabolite dihydrotestosterone (DHT), on hormone-sensitive cells. A typical, neutral scenario for its use involves the initial phases of androgen deprivation therapy, where control over hormonal signaling is critical. The drug acts by blocking the androgen receptor signal, which essentially means it competitively prevents these growth-stimulating hormones from binding to their target cellular receptors. By interfering with this crucial hormonal signaling pathway, the medication helps manage conditions where cell proliferation is reliant upon the continuous stimulation provided by androgens.

What side effects are possible with Fluxus?

Possible Side Effects and Safety Information

The safety profile for Fluxus (Flutamide) is defined by officially classified adverse reactions and specific safety constraints documented by regulatory authorities, including the EMA and FDA. Side effects are grouped by frequency, as presented in official prescribing information.


Frequency-Classified Adverse Reactions

Classification Examples of Officially Listed Adverse Reactions
Very Common Gynaecomastia (breast enlargement), breast tenderness, hot flushes, and diarrhoea.
Common Transient abnormal liver function, fatigue, insomnia, and nausea/vomiting.
Rare to Very Rare Hepatitis, interstitial pneumonitis, malignant male breast neoplasms, and photosensitivity reactions.

Serious Adverse Reactions and Systemic Safety

Flutamide is associated with the potential for severe hepatic injury, including documented cases of fatal hepatic failure and hepatic encephalopathy. The label includes high-level warnings concerning these hepatobiliary disorders. The medicine also carries a rare risk of serious blood and lymphatic system disorders, such as methemoglobinemia and certain types of anaemia.

Safety notes specify time-related patterns, noting that approximately half of the reported cases of serious hepatic injury occurred within the initial three months of treatment. Regulatory documents, therefore, mandate that liver function tests be obtained before starting treatment and periodically thereafter.


Population-Specific Safety Constraints

The medication is contraindicated in women, including those who are or may become pregnant, due to the risk of fetal harm. It is also strictly contraindicated for male patients with a history of severe hepatic impairment or markedly elevated baseline serum transaminase levels.

Overdose and Emergency Response

Documented overdose presentations of the active ingredient Flutamide involve clinical signs such as breast enlargement (gynecomastia) and breast tenderness, in addition to laboratory findings of increased serum transaminase (SGOT) levels.

While a single dose considered definitively life-threatening has not been established in regulatory documents, the official label reports animal study findings of ataxia, slow respiration, hypoactivity, and piloerection.

Regulatory information indicates potential effects on the hepatic system (transaminase elevation) and neurological system (including risk of seizure).

When Urgent Medical Help Is Required

Immediate medical attention is required for any suspected overdose. Emergency services must be contacted if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. Contacting the Poison Control helpline is also a mandated immediate action.

Supportive Management and Constraints

Regulatory documents state that no specific antidote is known for Flutamide overdose. Management is limited to general supportive care, including frequent monitoring of vital signs and close observation of the patient.

Management is further constrained by the fact that the substance is highly protein bound and is not cleared by hemodialysis. The elimination half-life of the active metabolite is noted as slightly prolonged in patients with severe renal impairment and in older individuals.

Therapeutic Uses of Fluxus

What Fluxus Treats: Main Uses and Benefits

Fluxus (fluoxetine) is a medication generally applied across therapeutic domains that involve certain distressing symptoms and conditions characterized by periods of heightened symptoms. Its role is relevant for easing and managing symptoms that interfere with daily functioning. Therapeutic uses may include conditions such as major depressive episodes, obsessive-compulsive disorder (OCD), and bulimia nervosa. This treatment is commonly used when short-term symptomatic assistance is needed to address symptom clusters that may become intense or disruptive.

The medication is applied in addressing symptoms related to systemic imbalance and contributes to easing the overall symptom load during periods of heightened symptoms. This approach may assist with preserving a sense of stability and supports patients during episodes of heightened discomfort during symptomatic phases. The treatment provides support that helps ease the overall symptom burden and helps improve day-to-day comfort during symptomatic periods.


Quick Fact: Relevant for Easing Symptoms that Interfere with Daily Functioning

Eligibility and Restrictions for Use

Who Can and Cannot Use Fluxus?

Eligibility for Fluxus (Flutamide) is highly specific and restricted, based on official government regulatory documents. The medicine is only intended for use in adult male patients for the treatment of specific forms of prostatic carcinoma.


Absolute Contraindications (Who Must Not Use)

Fluxus is strictly prohibited in several patient populations:

  • All women/females: The drug has no approved indication for women and is contraindicated due to potential for fetal harm.
  • Severe Hepatic Impairment: Patients with severe liver disease or critically high baseline liver enzyme levels must not use Fluxus.
  • Hypersensitivity: Patients with known allergy or hypersensitivity to Flutamide or any excipient in the formulation.

Age and Condition Restrictions

The medication's safety and efficacy have not been established in the pediatric population (patients under 18 years old), and its use is unauthorized in children. Use requires caution and monitoring in adult males with pre-existing conditions, including impaired renal function, pre-existing hepatic dysfunction, and certain cardiac conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes officially documented interaction patterns for Fluxus (Flutamide), based strictly on regulatory prescribing information.


Documented Drug-Drug Interactions

Interaction Type Interacting Substance/Class Official Regulatory Finding
Increased Exposure Risk Strong CYP1A2 Inhibitors (e.g., Teriflunomide) Co-administration may increase the serum concentration and systemic exposure of Flutamide or its active metabolite.
Anticoagulant Effect Oral Anticoagulants (e.g., Warfarin) Concomitant use is associated with a documented increase in Prothrombin Time (PT), requiring monitoring of coagulation status.
Pharmacodynamic Risk QTc-Prolonging Medicinal Products Use requires careful evaluation due to the risk of additive QTc interval prolongation.

Other Documented Product Interactions and Restrictions

Interaction Type Substance/Condition Regulatory Constraint
Substance Avoidance Excessive Alcohol Consumption must be avoided due to the potential for enhanced liver toxicity.
Herbal/Supplement Maitake Documented in some sources as potentially increasing serum levels of Flutamide.
Population Constraint Severe Hepatic Impairment Flutamide is formally contraindicated in patients with this pre-existing condition.

Official regulatory documents require that the administration of Flutamide should commence at least three days before starting an LHRH-agonist for combination therapy. Specific populations, including patients with G6PD deficiency and smokers, are identified as having an increased risk of toxicity from the active metabolite, such as methemoglobinemia.

Mechanism of Action

Androgen Receptor Competitive Antagonism

Flutamide's mechanism is initiated by its active metabolite, 2-hydroxyflutamide, which acts as a competitive antagonist at the Androgen Receptor (AR), an intracellular protein found in sensitive cells. By occupying this receptor, the active metabolite prevents natural androgens, primarily Testosterone and Dihydrotestosterone (DHT), from initiating their molecular signal. This binding functionally modulates the androgen signaling pathway and halts the gene transcription required for cell growth and proliferation.

Disruption of the HPT-Axis Feedback Loop

The AR blockade also extends centrally to the Hypothalamus-Pituitary-Testicular (HPT) Axis, where it removes the body's natural negative feedback signal. The resulting physiological consequence is a compensatory surge in Luteinizing Hormone (LH), which stimulates the testicles to increase the release of testosterone into the circulation.

Functional Constraint: Mechanism Limitations

Since the drug only blocks the action of androgens at the receptor and not their production, the mechanism is functionally constrained, particularly against cells that evolve to bypass the requirement for AR activation, a state known as castration resistance.

Dosage and Administration Information

How to Use Fluxus

The administration of Fluxus (Flutamide) is governed by established protocols, ensuring its application adheres to standardized dosing and usage requirements. The medicine is exclusively for use in men and is most often employed as part of a combination treatment plan.


Administration and Dosing

The approved route of administration for Fluxus is oral (by mouth), utilizing the capsule or tablet form. The standard adult dose is 250 mg taken three times daily (TID), resulting in a total daily dose of 750 mg.

Dosing Parameter Official Instruction
Route of Administration Oral (Swallow capsule/tablet whole)
Standard Single Dose 250 mg
Dosing Frequency Three times daily (TID) at approximate 8-hour intervals
Total Daily Dose 750 mg

Use Protocol and Timing

Established instructions define specific timing requirements for initiating and continuing therapy:

  • Combination Therapy: When used with an LHRH agonist (the second drug in the regimen), Fluxus should be started simultaneously or 24 to 72 hours before the LHRH agonist is administered.
  • Radiation Therapy: When used with radiation, treatment should begin eight weeks prior to the start of radiation and continue throughout the course of the therapy.

General Usage Instructions

  • With/Without Food: Fluxus can be taken with or without food.
  • Missed Dose: If a dose is missed, patients should skip the missed dose and resume the regular schedule; the dose should not be doubled to compensate.
  • Specific Populations: No routine dose adjustment is generally required for older adults or those with renal impairment. However, use in patients with hepatic impairment requires careful assessment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fluxus (Flutamide)


Evidence for Use in Advanced Prostate Carcinoma

The primary research for Fluxus was evaluated in men diagnosed with advanced prostate carcinoma that responds to hormonal treatments. This evidence base consists mainly of large-scale, international Randomized Controlled Trials (RCTs) and meta-analyses that combine data from many of these major trials. These studies explored Flutamide's use when added to forms of hormonal deprivation, a strategy often termed Maximal Androgen Blockade.

Researchers studies explored key measures such as Overall Survival and Time to Disease Progression. Studies also data show patterns related to the temporary testosterone surge known as a flare that may happen when initial hormonal therapy begins. The research base for advanced prostate carcinoma is described as having a High Evidence Level because it relies on the pooling of data from multiple large, well-designed RCTs.


Research on Hormonal Symptoms in Adult Women

Research has also was evaluated in women, focusing on conditions where symptoms are linked to excessive male hormones (androgens), such as hirsutism and features of Polycystic Ovary Syndrome (PCOS). This evidence is derived from typically smaller Controlled Trials and Systematic Reviews. These studies explored short- to intermediate-term outcomes related to physical discomfort and outcomes describing episodic or acute changes.

Findings contribute to understanding symptom patterns and how patient-reported outcomes describing perceived discomfort evolved in the observed populations. However, the evidence base for symptoms like hirsutism is generally described as having a Moderate Evidence Level. The studies often had follow-up durations that were limited, typically lasting 6 to 12 months, and relied on modest sample sizes.


Research Gaps and Areas of Uncertainty

The research on Fluxus studies explore gaps and uncertainties. A major limitation is that the key prostate carcinoma studies are historical. This means comparative evidence is lacking between Flutamide and many other antiandrogen regimens developed since its initial evaluation. For both indications, long-term effects are not fully established, and subgroup findings are uncertain, meaning detailed information for specific patient groups remains limited.

Key Studies & References Flutamide - NCI - National Cancer Institute (Regulatory/Indication Context)

Frequently Asked Questions (FAQ)

Common questions about Fluxus (FAQ)


Q: Is Fluxus the same type of medicine as [similar common drug]?

A: Fluxus (Flutamide) is officially classified as a Nonsteroidal Antiandrogen and an Antineoplastic Agent in regulatory documents. This classification indicates that the medicine functions by blocking the effects of male hormones (androgens) on specific cells.

Q: Does Fluxus start working immediately?

A: Official information indicates that the active component of Fluxus is rapidly absorbed after it is taken by mouth. Its active form has a plasma half-life of approximately six hours, which describes the amount of time it remains in the body at a certain concentration. This is a measure of its presence, not the onset of clinical effect.

Q: Can Fluxus cause weight changes?

A: Regulatory documents list a few adverse reactions that may relate to weight, including edema (swelling due to fluid retention) and increased appetite. Weight decrease has also been documented as a possible adverse reaction to antiandrogens in official sources.

Q: Can Fluxus affect my ability to drive or operate machinery?

A: Regulatory warnings mention that adverse reactions such as fatigue, dizziness, confusion, and malaise have been reported by some patients. Official documents caution that these central nervous system effects may interfere with the ability to drive and use machines.

Q: Is Fluxus a long-term treatment or short-term?

A: Fluxus is typically indicated for the long-term treatment of advanced prostatic carcinoma. Regulatory documents indicate that therapy may continue long-term, often until there is evidence of disease progression.

Q: Are there any known interactions between Fluxus and herbal supplements?

A: While few specific supplements are listed in regulatory sources, official documents state that patients should inform their healthcare team about all prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products they are using. This practice helps healthcare professionals review potential interaction risks.

Q: Can Fluxus cause problems with sleep?

A: Yes, official regulatory documents list both insomnia (difficulty falling or staying asleep) and somnolence (drowsiness or sleepiness) among the common adverse reactions reported by patients using Fluxus.

Q: Is it true that Fluxus has different effects on men versus women?

A: Official documents note that the drug is only indicated for use in men and is strictly prohibited in women, including those who are or may become pregnant. The prohibition is based on the documented risk of fetal harm associated with the medication.

Q: Why do some people report feeling [vague symptom, e.g., 'foggy'] when they start Fluxus?

A: Official patient information lists several central nervous system (CNS) reactions, including confusion, dizziness, nervousness, and somnolence (drowsiness). Regulatory documents note that in rare cases related to liver problems, cognitive effects, which patients may describe as 'fogginess,' have been reported.

Q: Is it okay to take Fluxus with antacids or heartburn medicine?

A: Official interaction lists do not typically include antacids as a direct documented interaction. However, official warnings exist regarding the use of products that can cause certain electrolyte disturbances, as this carries a potential risk of QTc prolongation (a heart rhythm issue).

Q: Does the efficacy of Fluxus decrease over time?

A: The clinical effectiveness of Fluxus is known to be limited in studies by cancer cells that evolve to bypass the need for the androgen receptor signal. This state is referred to as castration resistance in the scientific literature.

Q: Is Fluxus suitable for people with diabetes?

A: Regulatory documents state that using Fluxus with an LHRH-agonist (as part of combination therapy) may lead to a reduction in glucose tolerance and/or an increase in blood sugar. Regulatory documents indicate that patients with pre-existing diabetes may require monitoring of blood sugar levels when using this combination.

Q: Can taking Fluxus cause changes in blood pressure?

A: Yes, regulatory documents list high blood pressure (hypertension) as an adverse reaction that has been reported by some patients using Fluxus.

Q: What are the common reasons someone might be told they cannot use Fluxus?

A: The main reasons for absolute prohibition, or contraindication, are a known allergy (hypersensitivity) to the drug, being a woman/female patient, or having severe hepatic impairment (severe liver disease).

Q: What does the research say about the long-term safety of Fluxus?

A: Official documents describe known long-term risks, including the potential for severe, potentially fatal hepatic injury (liver damage). For this reason, regulatory documents require long-term monitoring of liver function tests.

Q: Is it normal to feel a bit nauseous when starting Fluxus?

A: Nausea and vomiting are listed as a very common adverse reaction in official safety documents, meaning they are frequently reported, especially when treatment is first initiated.

Q: Can Fluxus affect my mood or energy levels?

A: Yes, adverse reactions listed in official documents include fatigue (tiredness), insomnia (difficulty sleeping), anxiety, and depression. These are reported effects associated with the drug.

Q: Are there any known severe drug interactions that I should watch out for with Fluxus?

A: Official warnings exist for co-administration with oral anticoagulants (like Warfarin), requiring careful monitoring of blood clotting time. Warnings also apply to QTc-prolonging medicinal products, due to the risk of additive heart rhythm issues.

Q: What happens when I stop taking Fluxus?

A: Discontinuing the drug is expected to allow the body's natural hormone axis to resume its normal function. In some prostate cancer patients, a phenomenon called the antiandrogen withdrawal syndrome has been observed, where disease markers (like PSA) may temporarily decrease upon stopping the medication.

Q: What are the official guidelines regarding using Fluxus while pregnant?

A: Fluxus is contraindicated in women due to the risk of fetal harm. Regulatory documents specify that males with female partners of reproductive potential should employ effective contraception during the period of treatment.

Q: Is there any research on Fluxus use in teenagers?

A: The drug is not indicated for use in the pediatric population (patients under 18 years old). Regulatory documents state clearly that its safety and efficacy have not been established in children.

Q: Is Fluxus safe to take with common pain relievers like ibuprofen?

A: Official documents caution against using the medicine with QTc-prolonging medicinal products, which is a class that includes some pain relievers. It is important for all non-prescription pain relievers to be reviewed by a healthcare professional to confirm they do not belong to a cautioned class of medicines.

Q: Are there different forms of Fluxus (e.g., tablet, liquid)?

A: Fluxus is officially available as an oral capsule and as a tablet formulation, depending on the specific product brand and country of sale. No liquid form is officially documented.

How should Fluxus be stored and disposed of?

How to Store and Dispose of Fluxus (Flutamide)

Official Storage Conditions

Fluxus (Flutamide) capsules must be stored at Controlled Room Temperature (CRT), typically between 15°C and 30°C (59°F and 86°F), and should be kept in the original container. It is strictly required to keep the medicine out of the reach of children. The product must be protected from moisture, direct light, and excessive heat, and must not be frozen to maintain its stability.

Disposal Instructions

Unused or expired Fluxus should be returned to an authorized drug take-back program whenever possible. If a take-back option is unavailable, the capsules must not be flushed down a toilet or drain. Instead, they should be mixed with an unappealing substance, placed in a sealed bag, and discarded with household trash, following local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fluxus found in:

A-Z Index: